Codexis Stock News

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Codexis (NASDAQ:CDXS) was downgraded by equities researchers at ValuEngine from a “strong-buy” rating to a “buy” rating in a report released on Friday, ValuEngine reports. A number of other eq

REDWOOD CITY, Calif., April 30, 2020 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report first quarter 2020 financial results.

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Nuveen Asset Management LLC raised its position in Codexis, Inc. (NASDAQ:CDXS) by 9.2% during the fourth quarter, Holdings Channel reports. The firm owned 202,086 shares of the biotechnology company�

Bank of America Corp DE trimmed its position in Codexis, Inc. (NASDAQ:CDXS) by 32.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 46,340 shares of the biotechnolog

Codexis, Inc. (NASDAQ:CDXS) – Equities research analysts at Jefferies Financial Group reduced their Q1 2020 earnings per share estimates for Codexis in a research report issued on Tuesday, April 21s

Codexis, Inc. (NASDAQ:CDXS) Director Bernard J. Kelley sold 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $10.

The biotech is racing to produce remdesivir for as many COVID-19 patients as possible. Will it be enough?

Codexis, Inc. (NASDAQ:CDXS) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 5,180,000 shares, a decline of

Geode Capital Management LLC lifted its stake in shares of Codexis, Inc. (NASDAQ:CDXS) by 3.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 690,475 shares of

Assenagon Asset Management S.A. grew its position in Codexis, Inc. (NASDAQ:CDXS) by 83.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 553,229 shares of the